Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.11
-0.20 (-0.94%)
Jun 29, 2026, 10:56 AM EDT - Market open
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$728,772
Profits / Employee
-$816,272
Market Cap
1.87B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 298 | 28 | 10.37% | 298 | 0 |
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Monte Rosa Therapeutics | 187 |
| Absci | 140 |
| AnaptysBio | 104 |
| AtaiBeckley | 99 |
| Tyra Biosciences | 87 |
SNDX News
- 17 days ago - Syndax price target lowered to $31 from $34 at Guggenheim - TheFly
- 18 days ago - Syndax presents data from SAVE trial at EHA - TheFly
- 18 days ago - Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - GlobeNewsWire
- 18 days ago - Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology - GlobeNewsWire
- 20 days ago - Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Syndax Pharmaceuticals Proxy statement: Proxy filing - Filings